KeyCorp Has Optimistic Outlook of INSP FY2027 Earnings

Inspire Medical Systems, Inc. (NYSE:INSP) – Stock analysts at KeyCorp lifted their FY2027 earnings per share (EPS) estimates for shares of Inspire Medical Systems in a report issued on Sunday, January 25th. KeyCorp analyst B. Fishbin now forecasts that the company will earn $2.12 per share for the year, up from their prior forecast of $2.07. KeyCorp has a “Sector Weight” rating on the stock. The consensus estimate for Inspire Medical Systems’ current full-year earnings is $2.16 per share.

Inspire Medical Systems (NYSE:INSP) last issued its quarterly earnings results on Monday, November 3rd. The company reported $0.38 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.15) by $0.53. Inspire Medical Systems had a return on equity of 9.41% and a net margin of 5.05%.The firm had revenue of $224.50 million during the quarter, compared to the consensus estimate of $220.39 million. During the same period last year, the business posted $0.60 EPS. The business’s revenue was up 10.5% compared to the same quarter last year.

A number of other research analysts have also weighed in on INSP. Piper Sandler lifted their target price on Inspire Medical Systems from $135.00 to $165.00 and gave the company an “overweight” rating in a report on Monday, December 8th. Mizuho upped their target price on Inspire Medical Systems from $110.00 to $130.00 and gave the stock an “outperform” rating in a research note on Wednesday, December 17th. Zacks Research raised Inspire Medical Systems from a “strong sell” rating to a “hold” rating in a research note on Monday, October 27th. Morgan Stanley restated an “equal weight” rating and set a $130.00 price target (up previously from $105.00) on shares of Inspire Medical Systems in a report on Tuesday, December 2nd. Finally, Evercore ISI reaffirmed an “outperform” rating and set a $125.00 target price on shares of Inspire Medical Systems in a research note on Thursday, January 22nd. Eight equities research analysts have rated the stock with a Buy rating, ten have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of “Hold” and an average target price of $133.47.

Inspire Medical Systems Stock Performance

Shares of NYSE:INSP opened at $81.72 on Tuesday. Inspire Medical Systems has a fifty-two week low of $70.77 and a fifty-two week high of $203.12. The company’s 50-day moving average is $105.96 and its 200 day moving average is $95.87. The company has a market capitalization of $2.37 billion, a P/E ratio of 55.59, a price-to-earnings-growth ratio of 8.28 and a beta of 0.72.

Institutional Investors Weigh In On Inspire Medical Systems

Large investors have recently modified their holdings of the business. Manning & Napier Advisors LLC acquired a new position in shares of Inspire Medical Systems during the 3rd quarter worth about $32,000. CWM LLC grew its holdings in Inspire Medical Systems by 216.1% in the 4th quarter. CWM LLC now owns 354 shares of the company’s stock valued at $33,000 after buying an additional 242 shares in the last quarter. V Square Quantitative Management LLC purchased a new stake in shares of Inspire Medical Systems in the fourth quarter valued at about $40,000. Larson Financial Group LLC raised its position in shares of Inspire Medical Systems by 21,266.7% during the 3rd quarter. Larson Financial Group LLC now owns 641 shares of the company’s stock valued at $48,000 after buying an additional 638 shares during the period. Finally, Pilgrim Partners Asia Pte Ltd acquired a new position in shares of Inspire Medical Systems in the 3rd quarter valued at $49,000. Institutional investors own 94.91% of the company’s stock.

Insider Buying and Selling at Inspire Medical Systems

In other Inspire Medical Systems news, Director Shawn Mccormick sold 2,000 shares of the company’s stock in a transaction that occurred on Friday, November 28th. The stock was sold at an average price of $127.48, for a total transaction of $254,960.00. Following the sale, the director directly owned 26,046 shares in the company, valued at $3,320,344.08. This represents a 7.13% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this link. Company insiders own 2.30% of the company’s stock.

Inspire Medical Systems Company Profile

Inspire Medical Systems, Inc is a medical technology company specializing in implantable neurostimulation devices for the treatment of obstructive sleep apnea (OSA). The company’s flagship offering, the Inspire® system, delivers targeted stimulation of the hypoglossal nerve to maintain airway patency during sleep, providing an alternative therapy for patients who are intolerant of or inadequately managed by continuous positive airway pressure (CPAP) devices.

The Inspire system comprises an implantable pulse generator, a sensing lead that monitors breathing patterns, and a stimulation lead that activates the hypoglossal nerve.